Pulse Biosciences, Inc.
PLSEHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pulse Biosciences, Inc. focuses on Medical Instruments & Supplies services and products. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. At a $3.78B market cap, Pulse Biosciences, Inc. ranks as a mid-cap company within healthcare. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
Market Cap
$3.78B
Beta
1.57
P/E (TTM)
—
P/E (Fwd)
-45.32
EPS (TTM)
$-1.18
EPS (Fwd)
$-1.17
ROE
-78.5%
ROA
-44.3%
Cash
$101.6M
Total Debt
$6.8M
Free CF
-$34.3M
52W Change
193.3%
Annual Financials
Cash vs Debt
Where PLSE stands vs its 150-day and 200-day moving averages
As of the September 11, 2026 close, PLSE finished 93.08% above its 150-day moving average ($28.19) and 120.63% above its 200-day moving average ($24.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PLSE overbought or oversold?
At the September 11, 2026 close, PLSE's RSI(14) was 63.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $101.6M in cash and $6.8M in debt, PLSE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$34.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -78.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $700K (2022) to $350K (2025), a 50% decline worth watching.
Pulse Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pulse Biosciences, Inc. and its sector.